68 related articles for article (PubMed ID: 16356581)
1. Treatment options in HBV.
Craxì A; Antonucci G; Cammà C
J Hepatol; 2006; 44(1 Suppl):S77-83. PubMed ID: 16356581
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
4. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
[TBL] [Abstract][Full Text] [Related]
5. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
Liaw YF
Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
[TBL] [Abstract][Full Text] [Related]
6. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
8. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
Sarin SK; Kumar M; Hissar S; Sharma BC
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
[TBL] [Abstract][Full Text] [Related]
9. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
10. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
[TBL] [Abstract][Full Text] [Related]
11. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.
Wiegand J; Hasenclever D; Tillmann HL
Antivir Ther; 2008; 13(2):211-20. PubMed ID: 18505172
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
13. Novel treatment options for hepatitis B virus infection.
Kumar R; Agrawal B
Curr Opin Investig Drugs; 2004 Feb; 5(2):171-8. PubMed ID: 15043391
[TBL] [Abstract][Full Text] [Related]
14. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
Chien RN; Liaw YF
Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259
[TBL] [Abstract][Full Text] [Related]
15. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B: therapeutic perspectives.
Rizzetto M; Lagget M
Forum (Genova); 2001; 11(2):137-50. PubMed ID: 11948359
[TBL] [Abstract][Full Text] [Related]
17. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
18. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
19. Changes in serological markers of hepatitis B virus after renal transplantation.
Urbini Dos Santos C; Sevá-Pereira T; Alves-Filho G; Lorena SL; Soares EC; Mazzali M
Transplant Proc; 2008 Apr; 40(3):749-51. PubMed ID: 18455006
[TBL] [Abstract][Full Text] [Related]
20. Management of chronic hepatitis B virus infection: a new era of disease control.
Farrell GC; Teoh NC
Intern Med J; 2006 Feb; 36(2):100-13. PubMed ID: 16472264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
